Russia supplies medicine against covid-19 to Latin America without including Mexico

MEXICO CITY (apro) .- The Russian Direct Investment Fund (RDIF) and the ChemRar Group have agreed to supply 17 countries with Avifavir, Russia’s first drug approved for the treatment of covid-19. Among the nations that have the drug are 11 from Latin America, which is not included Mexico.

According to a statement posted on the RDIF website, Avifavir will be delivered to Argentina, Bulgaria, Brazil, Chile, Colombia, Ecuador, El Salvador, Honduras, Kuwait, Panama, Paraguay, Saudi Arabia, Serbia, Slovakia, South Africa, United Arab Emirates and Uruguay.

The drug has previously been delivered to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan, he added.

Russia approves Coronavir, the first drug against covid-19 for sale in pharmacies

Avifavir, the statement highlights, is the first drug registered in the world made based on the substance favipiravir against the coronavirus and the first in Russia approved for the treatment of covid-19.

In its statement, Russia’s sovereign wealth fund recalled that on May 29 Avifavir received a registration certificate from the Russian Ministry of Health and became the first favipiravir-based medicine in the world approved for the treatment of covid- 19.

He also highlighted that approximately five months after the Avifavir clinical trials in Russia, Fujifilm from Japan confirmed the efficacy of favipiravir against the novel coronavirus infection.

“Avifavir is now Russia’s leading anticovid drug in terms of exports. In particular, on September 21 the start of deliveries to Bolivia and other Latin American countries was announced as part of the agreement to deliver 150,000 packages. Avifavir has also been approved by regulators in Europe, the Middle East and Asia ”, underlined the RDIF.

Russia will present its treatment against covid-19 to Latin America

“When we registered the world’s first favipiravir-based coronavirus drug, there was a lot of skepticism as people wondered how we could register it when Japan had not yet registered it,” said Kirill Dmitriev, CEO of Russia’s Direct Investment Fund.

“Now, five months after our clinical trials, we see that Japan has confirmed the clinical efficacy of favipiravir. Avifavir has been tested in more than 1,300 patients, including 408 patients in clinical trials and 940 patients during the post-registration observational clinical trial, ”he explained.

Dmitriev concluded in the release that Avifavir is also three to four times cheaper than Remdesivir, the drug approved by the United States for the treatment of Covid-19.

The price of remdesivir, a treatment for covid-19, outrages US consumers

.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.